ATYR (aTyr Pharma Inc) vs S&P 500 Comparison

ATYR

S&P 500

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ATYR

S&P 500

Difference

1Y 3Y 5Y 10Y 15Y 20Y

ATYR

S&P 500

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

S&P 500

ATYR

ABBV

AMGN

GILD

VRTX

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

aTyr Pharma Inc
Glance View

Market Cap

324m USD

Industry

Biotechnology

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. The company is headquartered in San Diego, California and currently employs 49 full-time employees. The company went IPO on 2015-05-07. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The firm is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.

View ATYR Analysis

ATYR Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

	Franklin Covey Co NYSE:FC	35.24 USD -2.49%
	Mohawk Industries Inc NYSE:MHK	117.065 USD -0.6%
	Ardmore Shipping Corp NYSE:ASC	12.63 USD 4.38%
	ASGN Inc NYSE:ASGN	86.135 USD 1.01%
	Skyworks Solutions Inc NASDAQ:SWKS	93.16 USD 2.49%
	Weatherford International PLC NASDAQ:WFRD	75.32 USD 2.46%

	Johnson & Johnson NYSE:JNJ	146.55 USD 2.01%
	Bank of America Corp NYSE:BAC	46.375 USD 2.15%
	Mastercard Inc NYSE:MA	513.015 USD 0.21%
	Salesforce Inc NYSE:CRM	325.66 USD -1.47%
	Abbvie Inc NYSE:ABBV	179.61 USD -0.27%
	Home Depot Inc NYSE:HD	386.05 USD -0.85%

	Arista Networks Inc NYSE:ANET	116.28 USD -2.27%
	Visa Inc NYSE:V	314.8735 USD 0.59%
	Texas Pacific Land Corp NYSE:TPL	1 275.59 USD 3.99%
	KLA Corp NASDAQ:KLAC	694.68 USD 0.63%
	Manhattan Associates Inc NASDAQ:MANH	266.945 USD -1.63%
	Pinduoduo Inc NASDAQ:PDD	99.985 USD 0.97%

	Salesforce Inc NYSE:CRM	325.66 USD -1.47%
	ServiceNow Inc NYSE:NOW	1 050 USD -2.51%
	EOG Resources Inc NYSE:EOG	128.01 USD 1.28%
	Copart Inc NASDAQ:CPRT	56.19 USD -0.69%
	Applied Materials Inc NASDAQ:AMAT	179.16 USD 0.95%
	Synopsys Inc NASDAQ:SNPS	491.14 USD -1.98%

	Johnson & Johnson NYSE:JNJ	146.55 USD 2.01%
	Berkshire Hathaway Inc NYSE:BRK.A	680 008.515 USD 0.5%
	Bank of America Corp NYSE:BAC	46.375 USD 2.15%
	Mastercard Inc NYSE:MA	513.015 USD 0.21%
	UnitedHealth Group Inc NYSE:UNH	513.84 USD 0.03%
	Exxon Mobil Corp NYSE:XOM	109.08 USD 1.24%

ATYR

vs

S&P 500

Stocks Performance
ATYR vs S&P 500

Performance Gap
ATYR vs S&P 500

Performance By Year
ATYR vs S&P 500

Competitors Performance
aTyr Pharma Inc vs Peers

aTyr Pharma Inc
Glance View

Company

Help

Tools

Stocks

FR		Pharnext SCA OTC:PNEXF	Add
US		Abbvie Inc NYSE:ABBV	Add
US		Amgen Inc NASDAQ:AMGN	Add
US		Gilead Sciences Inc NASDAQ:GILD	Add
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	Add
US	E	Epizyme Inc F:EPE	Add
AU		CSL Ltd ASX:CSL	Add
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	Add
US	S	Seagen Inc F:SGT	Add
NL		argenx SE XBRU:ARGX	Add

FR		Pharnext SCA OTC:PNEXF	Select
US		Abbvie Inc NYSE:ABBV	Select
US		Amgen Inc NASDAQ:AMGN	Select
US		Gilead Sciences Inc NASDAQ:GILD	Select
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	Select
US	E	Epizyme Inc F:EPE	Select
AU		CSL Ltd ASX:CSL	Select
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	Select
US	S	Seagen Inc F:SGT	Select
NL		argenx SE XBRU:ARGX	Select

CA	A	Advance Lithium Corp XTSX:AALI	Add
US	G	GE Vernova LLC NYSE:GEV	Add
NL	N	Nepi Rockcastle NV JSE:NRP	Add
US		Schlumberger NV NYSE:SLB	Add
US	B	Baker Hughes Co NASDAQ:BKR	Add
ID		Amman Mineral Internasional Tbk PT IDX:AMMN	Add
US	R	Reddit Inc NYSE:RDDT	Add
CH	G	Galderma Group AG SIX:GALD	Add
US		Halliburton Co NYSE:HAL	Add
IN		Jio Financial Services Ltd NSE:JIOFIN	Add

ATYR vs S&P 500

Stocks Performance ATYR vs S&P 500

Performance Gap ATYR vs S&P 500

Performance By Year ATYR vs S&P 500

Competitors Performance aTyr Pharma Inc vs Peers

aTyr Pharma Inc Glance View

Company

Help

Tools

Stocks

ATYR

vs

S&P 500

Stocks Performance
ATYR vs S&P 500

Performance Gap
ATYR vs S&P 500

Performance By Year
ATYR vs S&P 500

Competitors Performance
aTyr Pharma Inc vs Peers

aTyr Pharma Inc
Glance View